Wound Care Treatment

At MGM Partners, we take pride in offering physicians an unparalleled wound care solution that stands above the rest. As your trusted partner, we are dedicated to delivering exceptional services that not only benefit you but also ensure optimal care for your patients. 

1. Highest Compensation Rates: Our commitment to physician satisfaction is unwavering. By partnering with MGM Partners, you gain access to the best reimbursement rates in the industry. We go the extra mile to secure higher compensation for your valuable expertise and dedication.
2. Guaranteed Service Excellence: With MGM Partners, you can be confident that your patients will receive the highest standard of wound care. We adhere to stringent protocols and employ advanced techniques to ensure optimal outcomes. Your patients' well-being and satisfaction are our top priorities.
3. Unrivaled Expertise: Backed by a team of experienced wound care specialists, we possess extensive knowledge and expertise in managing complex wounds. Our commitment to continuous learning and innovation ensures that you receive the most up-to-date treatments and approaches.
4. Comprehensive Solutions: We offer a comprehensive range of wound care services, tailoring our solutions to meet the unique needs of your patients. From advanced wound dressings to bioengineered grafts, we provide cutting-edge options that facilitate effective wound healing.

• Our wound care services offer the industry's best reimbursement rates, providing significant financial benefits for healthcare professionals.
• We deliver the highest quality biologics, ensuring optimal outcomes for patients.
• With our stringent HydraTek® process, we maintain unrivaled standards of quality and safety.
• MGM Partners has an impeccable safety record, having successfully produced and implanted countless grafts.
• We provide a comprehensive range of indications, catering to various medical needs.

Abstract: Injuries to the skin are extensively costly to the health care

system. When caused by metabolic and vascular compromise, these

injuries are even more foreboding for patients. They can result in

chronic inflammation, reduced mobility, and chronic pain. Materials

and Methods. Twenty patients were selected from the author’s patient

population at the West Boca Center for Wound Healing for a retrospective

cohort study. Patients underwent a run-in period of 2 weeks, where

standard of care was used to clear the wound of bioburden. A dehydrated,

human amniotic membrane (dHAM; WoundEx Membrane, Skye

Biologics, Inc, El Segundo, CA) was applied at weeks 1 (2 weeks post

run-in), 3, and 5, if necessary. Wound measurements and photographs

were performed weekly. Data were collected through a standard form in

each patient’s medical record to improve reliability and reproducibility.

The data extraction was performed by the author and to reduce bias.

Reduction of bias was performed by selecting patients whose wounds

already were established and in temporal sequence. Results. In this

review of 20 patients treated with the dHAM, the author was able to

effectively close all wounds in approximately 9.9 weeks (69.3 days). A

linear relationship was discovered between wound size in cm2 and days

to closure. Diabetic foot ulcers closed on average in 11.8 weeks (82.6

days) and venous leg ulcers in 9.2 weeks (64.4 days). No adverse

events were noted secondary to the dHAM application, which shows

this is a safe and effective treatment option. As of the date of this publication,

there is no recurrence of the ulcerations noted. Conclusion.

The use of this particular dHAM allograft effectively closed diabetic

foot ulcerations in 82.6 days and median wound closure in 69.3 days.

This poses as an advantageous clinical benefit in the scope of treatment

of lower extremity wounds.

Key words: amniotic allografts, wound regeneration, advanced wound

care, diabetes, healing rate, remodeling

Wounds Epub 2017 January 23